bowel

Eli Lilly to buy bowel disease drug developer Morphic for $3.2 billion By Reuters

(Reuters) - Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug…

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only…

Investor Empires

This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire…

Teva teams with Sanofi on inflammatory bowel treatment

Investor Empires

Israeli drug developer Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and French pharmaceutical company Sanofi (Nasdaq: SNY; Euronext: SAN) have today announced a collaboration to develop and commercialize…